Peripheral Neuropathy Trial, Recruiting NCT06763575 Sponsor: Department of Medical Services Ministry of Public Health of Thailand Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06763575
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be willing to sign a consent form agreeing to take part in the study
  • You must be 18 years old or older at the time of signing the consent form
  • You must have been diagnosed with a solid tumour (such as breast cancer or lung cancer)
  • You must be scheduled to receive a chemotherapy drug called paclitaxel, given through a drip (IV), once every 3 weeks

Who may not be able to join:

  • You have previously received certain chemotherapy drugs (such as taxane-based, platinum-based, or anti-microtubule drugs) that are known to cause nerve damage
  • You have a history of nerve damage or nerve-related problems (called neuropathy)
  • You have a history of carpal tunnel syndrome (a condition causing numbness or tingling in the hand and wrist)
  • You have a history of allergic reactions to latex or gloves
  • You are currently receiving any treatments that may help nerve-related conditions, such as certain medications (for example amitriptyline, gabapentin), supplements, acupuncture, cold therapy, or exercise therapy
  • You have a history of Raynaud's phenomenon (a condition where fingers and toes change colour and feel numb in the cold)
  • You have wounds or large scars on your hands
  • You are currently pregnant or breastfeeding
  • You have poorly controlled diabetes, shown by a blood sugar level measurement called HbA1c being above 6.5 (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sunatee Sa-nguansai, M.D., Department of Medical Services Ministry of Public Health of Thailand

Phone: +66805564241

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Department of Medical Services Ministry of Public Health of Thailand
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
1 January 2026

Where this trial is recruiting

🇹🇭 Thailand

Primary endpoints

Incidence of grade 2 or higher paclitaxel-induced sensory peripheral neuropathy using CTCAE version 5.0.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov